Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$174.72 USD

174.72
8,241,747

+0.30 (0.17%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $175.51 +0.79 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Zacks Equity Research

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

Johnson & Johnson (JNJ) closed at $177.71 in the latest trading session, marking a -1.01% move from the prior day.

Zacks Equity Research

Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?

Smart Beta ETF report for QUS

Zacks Equity Research

Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?

Smart Beta ETF report for VIG

Zacks Equity Research

The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer

AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog

Zacks Equity Research

J&J (JNJ) Carvykti Gets EU Nod for Advanced Multiple Myeloma

The European Commission approved J&J's (JNJ) BCMA-directed CAR-T cell therapy, Carvykti to treat patients with multiple myeloma who have already received multiple treatments.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids

European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.

Zacks Equity Research

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $179.46, marking a -0.09% move from the previous day.

Zacks Equity Research

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

The Zacks Analyst Blog Highlights Johnson & Johnson, Walt Disney, NextEra Energy, The Home Depot and Anthem

Johnson & Johnson, Walt Disney, NextEra Energy, The Home Depot and Anthem have been included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Johnson & Johnson, Walt Disney & NextEra Energy

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and NextEra Energy, Inc. (NEE).

Zacks Equity Research

Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5

Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.

Zacks Equity Research

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

Style Box ETF report for VTV

Zacks Equity Research

Zacks Investment Ideas feature highlights: The Health Care Select Sector SPDR ETF and Johnson and Johnson

The Health Care Select Sector SPDR ETF and Johnson and Johnson have been highlighted in this Investment Ideas article.

Bryan Hayes headshot

Healthcare Outperformance May Signal Short-Term Market Bottom

This sector outperformance may be a sign the market is nearing a point of selling exhaustion.

Neena Mishra headshot

Best ETFs for High Inflation and Rising Rates

We discuss areas that could outperform in the current market environment.

Zacks Equity Research

Johnson & Johnson (JNJ) Down 4.6% Since Last Earnings Report: Can It Rebound?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio

We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.

Zacks Equity Research

Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?

Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.

Zacks Equity Research

Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?

Style Box ETF report for SCHV

Zacks Equity Research

Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?

Style Box ETF report for IWD